Chronic Treatment with Olanzapine Increases Adiposity by Changing Fuel Substrate and Causes Desensitization of the Acute Metabolic Side Effects

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2013 Nov 6

PMID 24190543

Citations 3

Authors

Elodie M Girault

Bruno Guigas

Anneke Alkemade

Ewout Foppen

Mariette T Ackermans

Susanne E la Fleur

Eric Fliers

Andries Kalsbeek

Affiliations

Soon will be listed here.

Abstract

Atypical antipsychotic drugs such as olanzapine induce weight gain and metabolic changes associated with the development of type 2 diabetes. The mechanisms underlying these metabolic side-effects are unknown at the moment. In this study, we investigated the metabolic changes induced by a chronic treatment, as well as the influence of a preceding chronic treatment on the acute effects of olanzapine on glucose metabolism. The effect of chronic olanzapine treatment (±6.5 mg/kg/day, administered via drinking water) on body weight, locomotor activity, body temperature, fat distribution and energy expenditure was investigated in male rats. After 5 weeks, the animals received an acute olanzapine challenge (intragastric, IG) at 3 mg/kg/h during 160 min to investigate the acute effects of olanzapine on glucose metabolism. Chronic olanzapine-treated animals showed a slight decrease in nocturnal body temperature, and increased perirenal fat pad weights as well as plasma leptin. In addition, chronic olanzapine-treated animals showed hyperinsulinaemia with unchanged blood glucose concentrations. The acute challenge with IG olanzapine elevated blood glucose levels and endogenous glucose production in control animals, but not in chronic olanzapine-pre-treated rats. Chronic olanzapine-treated animals also showed reduced locomotor activity and a higher respiratory exchange ratio. Thus, chronic treatment with olanzapine in rats causes desensitization to its acute effects on glucose metabolism but promotes adiposity probably due to a shift from lipids to carbohydrates as an energy source. Chronic exposure to olanzapine changes body fat distribution and insulin sensitivity in an unfavourable direction, but it is still unclear what the primary mechanism is.

Citing Articles

Perirenal Adipose Tissue: Clinical Implication and Therapeutic Interventions.

Fazeli S, Nourollahi S, Alirezaei A, Mirhashemi S, Davarian A, Hosseini I Indian J Nephrol. 2024; 34(6):573-582.

PMID: 39649326 PMC: 11619052. DOI: 10.25259/ijn_532_23.

A comprehensive approach to predicting weight gain and therapy response in psychopharmacologically treated major depressed patients: A cohort study protocol.

Simon M, Barton B, Glocker C, Musil R PLoS One. 2022; 17(7):e0271793.

PMID: 35862413 PMC: 9302848. DOI: 10.1371/journal.pone.0271793.

The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance.

Li R, Ou J, Li L, Yang Y, Zhao J, Wu R Front Pharmacol. 2018; 9:379.

PMID: 29713286 PMC: 5911481. DOI: 10.3389/fphar.2018.00379.

References

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

Evers S, Calcagnoli F, van Dijk G, Scheurink A . Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacol Biochem Behav. 2010; 97(1):163-9. DOI: 10.1016/j.pbb.2010.05.029. View

Houseknecht K, Robertson A, Zavadoski W, Gibbs E, Johnson D, Rollema H . Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2006; 32(2):289-97. DOI: 10.1038/sj.npp.1301209. View

Davey K, OMahony S, Schellekens H, OSullivan O, Bienenstock J, Cotter P . Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl). 2012; 221(1):155-69. DOI: 10.1007/s00213-011-2555-2. View

van der Zwaal E, Luijendijk M, Adan R, la Fleur S . Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol. 2008; 585(1):130-6. DOI: 10.1016/j.ejphar.2007.11.078. View

Stefanidis A, Verty A, Allen A, Owens N, Cowley M, Oldfield B . The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring). 2008; 17(1):16-24. DOI: 10.1038/oby.2008.468. View

Minet-Ringuet J, Even P, Goubern M, Tome D, de Beaurepaire R . Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite. 2006; 46(3):254-62. DOI: 10.1016/j.appet.2006.01.008. View

Chintoh A, Mann S, Lam L, Lam C, Cohn T, Fletcher P . Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol. 2008; 28(5):494-9. DOI: 10.1097/JCP.0b013e318184b4c5. View

Aichhorn W, Whitworth A, Weiss E, Hinterhuber H, Marksteiner J . [Differences between men and women in side effects of second-generation antipsychotics]. Nervenarzt. 2006; 78(1):45-52. DOI: 10.1007/s00115-006-2112-0. View

10.

Mattiuz E, Franklin R, Gillespie T, Murphy A, Bernstein J, Chiu A . Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab Dispos. 1997; 25(5):573-83. View

11.

Kapur S, VanderSpek S, Brownlee B, Nobrega J . Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003; 305(2):625-31. DOI: 10.1124/jpet.102.046987. View

12.

Weston-Green K, Huang X, Deng C . Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One. 2012; 7(3):e33548. PMC: 3306411. DOI: 10.1371/journal.pone.0033548. View

13.

Phan T, Yu R, Hersch M . Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome. Med J Aust. 1998; 169(4):230-1. DOI: 10.5694/j.1326-5377.1998.tb140236.x. View

14.

Aravagiri M, Teper Y, Marder S . Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos. 2000; 20(8):369-77. DOI: 10.1002/1099-081x(199911)20:8<369::aid-bdd200>3.0.co;2-6. View

15.

Haack S, Seeringer A, Thurmann P, Becker T, Kirchheiner J . Sex-specific differences in side effects of psychotropic drugs: genes or gender?. Pharmacogenomics. 2009; 10(9):1511-26. DOI: 10.2217/pgs.09.102. View

16.

Llorente-Berzal A, Mela V, Borcel E, Valero M, Lopez-Gallardo M, Viveros M . Neurobehavioral and metabolic long-term consequences of neonatal maternal deprivation stress and adolescent olanzapine treatment in male and female rats. Neuropharmacology. 2011; 62(3):1332-41. DOI: 10.1016/j.neuropharm.2011.07.031. View

17.

McNamara R, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton J . Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity. Schizophr Res. 2011; 129(1):66-73. PMC: 3100393. DOI: 10.1016/j.schres.2011.03.016. View

18.

Terry Jr A, Warner S, Vandenhuerk L, Pillai A, Mahadik S, Zhang G . Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience. 2008; 156(4):1005-16. PMC: 2642674. DOI: 10.1016/j.neuroscience.2008.08.030. View

19.

van der Zwaal E, Luijendijk M, Evers S, la Fleur S, Adan R . Olanzapine affects locomotor activity and meal size in male rats. Pharmacol Biochem Behav. 2010; 97(1):130-7. DOI: 10.1016/j.pbb.2010.05.009. View

20.

Albaugh V, Judson J, She P, Lang C, Maresca K, Joyal J . Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. 2010; 16(5):569-81. PMC: 2892549. DOI: 10.1038/mp.2010.33. View